tirzepatide compounding deadline 📢 FDA has determined the shortage of semaglutide injection products, a glucagon-like peptide 1 (GLP-1) medication, is resolved. Patients and prescribers may still see intermittent and limited localized supply disruptions as the Zepbound No Longer in Shortage:

The CT and MRI images were automatically matched, and the images were checked in all directions and modified, if necessary, by a primary physician

(Part 2) 4 Highlights from the HPLC2026 Conference through the Lens of LC Troubleshooting 5

CEO David Ricks framed it simply: "We reached millions more patients launching Inluriyo, expanding Mounjaro and Kisunla globally, and submitting orforglipron for approval." 2026 Guidance Leaves No Room for Doubt Lilly guided 2026 revenue to $80-$83 billion

Ozempic is a brand name of semaglutide (generic name), and Mounjaro / Zepbound are brand names for tirzepatide (generic name)